Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcus BiosciencesRCUS +1.02%45 3-Year EBITDA Growth Rate is 4.50% as of Jun. 2026. GuruFocus rates RCUS with a GF Score™ of 45/100 and a GF Value™ of $7.29 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,132 Biotechnology companies, Arcus Biosciences ranks worse than 63.96% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Arcus Biosciences was 4.50% per year. The lowest was -39.20% per year. And the median was -22.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Arcus Biosciences 3-Year EBITDA Growth Rate Related Terms
RCUS vs ALMS, DNLI, NAMS: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Arcus Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 4.50% mean?
Arcus Biosciences (RCUS) has a 3-Year EBITDA Growth Rate of 4.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Arcus Biosciences and its competitors. According to the industry distribution chart, Arcus Biosciences ranks #724 out of 1132 companies in the Biotechnology industry, placing it in the top 64%.
Is Arcus Biosciences' 3-Year EBITDA Growth Rate too high?
Arcus Biosciences' current 3-Year EBITDA Growth Rate is 4.50%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Arcus Biosciences' value of 4.50% is 69.7% below this industry median. Based on the distribution chart, Arcus Biosciences ranks #724 out of 1132 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Arcus Biosciences has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' 3-Year EBITDA Growth Rate compare to ALMS and DNLI?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #724 out of 1132 companies for 3-Year EBITDA Growth Rate. This places Arcus Biosciences in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Arcus Biosciences' value of 4.50% is 69.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,132 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcus Biosciences's current 3-Year EBITDA Growth Rate of 4.50% is 69.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Arcus Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcus Biosciences's current 3-Year EBITDA Growth Rate is 4.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.29, compared to a current price of $28.62 — trading 292.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 4.50% and 69.7% below the Biotechnology industry median of 14.85. Arcus Biosciences' overall GF Score™ is 45/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current 3-Year EBITDA Growth Rate is 4.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcus Biosciences (RCUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued.
The current stock price of $28.62 is trading 292.6% above its estimated GF Value™ of $7.29.
GuruFocus considers Arcus Biosciences to be Significantly Overvalued.
Key valuation signals for RCUS:
3-Year EBITDA Growth Rate: 4.50%
GF Value™: $7.29 vs. price of $28.62 (292.6% above fair value)
Industry Position: 69.7% below the Biotechnology median (#724 of 1132)
No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
45GF Score
Get the complete analysis for RCUS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCUS has been successfully added to your 
